Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 8, 2013 - Issue 3
Submit an article Journal homepage
279
Views
18
CrossRef citations to date
0
Altmetric
Review

Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature

Courtney Aavang Tibble University of California at San DiegoSchool of Medicine, 9500 Gilman Dr, La Jolla,CA 92093, USA; University of California at San DiegoSchool of Medicine, 9500 Gilman Dr, La Jolla,CA 92093, USA
,
Tricia Santos Cavaiola University of California at San DiegoSchool of Medicine, 9500 Gilman Dr, La Jolla,CA 92093, USA; University of California at San DiegoSchool of Medicine, 9500 Gilman Dr, La Jolla,CA 92093, USA
&
Robert R Henry Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive CA 92122, USA. [email protected]; University of California at San DiegoSchool of Medicine, 9500 Gilman Dr, La Jolla,CA 92093, USA; Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive CA 92122, USA. [email protected]; University of California at San DiegoSchool of Medicine, 9500 Gilman Dr, La Jolla,CA 92093, USA
Pages 247-259 | Published online: 10 Jan 2014

References

  • Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4–14 (2010).
  • Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289(1), 76–79 (2003).
  • Fagot-Campagna A, Pettitt DJ, Engelgau MM et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J. Pediatr. 136(5), 664–672 (2000).
  • American Diabetes Association. Position statement. Standard of medical care in diabetes – 2012. Diabetes Care 35(Suppl. 1), S11–S63 (2012).
  • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 368(9548), 1696–1705 (2006).
  • Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol. Med. 14(4), 161–168 (2008).
  • Robles GI, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with Type 2 diabetes. Drug Des. Devel. Ther. 3, 219–240 (2009).
  • Chia CW, Egan JM. Incretin-based therapies in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 93(10), 3703–3716 (2008).
  • Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of Type 2 diabetes mellitus. Clin. Ther. 31(11), 2472–2488 (2009).
  • Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and bodyweight in subjects with Type 2 diabetes. Diabetes Care 30(6), 1487–1493 (2007).
  • Drucker DJ, Buse JB, Taylor K et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, noninferiority study. Lancet 372(9645), 1240–1250 (2008).
  • Buse JB, Drucker DJ, Taylor KL et al.; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weightloss over 52 weeks. Diabetes Care 33(6), 1255–1261 (2010).
  • Bergenstal RM, Wysham C, Macconell L et al.; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of Type 2 diabetes (DURATION-2): a randomised trial. Lancet 376(9739), 431–439 (2010).
  • Wysham C, Bergenstal R, Malloy J et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet. Med. 28(6), 705–714 (2011).
  • Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with Type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375(9733), 2234–2243 (2010).
  • Russell-Jones D, Cuddihy RM, Hanefeld M et al.; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with Type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35(2), 252–258 (2012).
  • Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 96(5), 1301–1310 (2011).
  • Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group. Potential of albiglutide, a long-acting GLP1 receptor agonist, in Type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32(10), 1880–1886 (2009).
  • Glaesner W, Vick AM, Millican R et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab. Res. Rev. 26(4), 287–296 (2010).
  • Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in Type 2 diabetic patients. Diabetes Care 22(7), 1137–1143 (1999).
  • Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 14(10), 882–892 (2012).
  • Minze MG, Dalal K, Irons BK. Removing barriers to insulin use. J. Fam. Pract. 60(10), 577–580 (2011).
  • Aroda VR, DeYoung MB. Clinical implications of exenatide as a twice-daily or once-weekly therapy for Type 2 diabetes. Postgrad. Med. 123(5), 228–238 (2011).
  • Buse JB, Nauck M, Forst T et al. Exenatide once weekly versus liraglutide once daily in patients with Type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381(9861), 117–124 (2013).
  • Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 30(8), 1448–1460 (2008).
  • Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care 27(11), 2628–2635 (2004).
  • Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care 28(5), 1092–1100 (2005).
  • Aroda VR, Henry RR, Han J et al. Efficacy of GLP1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin. Ther. 34(6), 1247.e22–1258.e22 (2012).
  • Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once-weekly or twice-daily. Diabet. Med. 26(7), 722–728 (2009).
  • Tomkin GH. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of Type 2 diabetes. Curr. Opin. Mol. Ther. 11(5), 579–588 (2009).
  • Bush MA, Matthews JE, De Boever EH et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes. Obes. Metab. 11(5), 498–505 (2009).
  • Rosenstock J, Stewart MW. Albiglutide. Drugs Fut. 35(9), 701–712 (2010).
  • Pratley R, Barnett A, Feinglos M et al. Efficacy and safety of once-weekly (qw) albiglutide vs. once-daily (qd) liraglutide in Type 2 diabetes (t2d) inadequately controlled on oral agents: Harmony 7 Trial. Presented at: ADA 72nd Scientific Sessions. Philadelphia, PA, USA, 8–12 June 2012.
  • Fonesca V, Ahren B, Chow F, et al. Once weekly GLP1 receptor agonist albiglutide vs prandial lispro added to basal glargine in Type 2 diabetes: similar glycemic control with weightloss and less hypoglycemia. Presented at: 48th EASD Annual Meeting. Berlin, Germany, 1–5 October 2012.
  • Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes. Obes. Metab. 13(5), 434–438 (2011).
  • Barrington P, Chien JY, Showalter HD et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with Type 2 diabetes. Diabetes. Obes. Metab. 13(5), 426–433 (2011).
  • Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd; EGO Study Group. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with Type 2 diabetes: the EGO study. Diabetes. Obes. Metab. 13(5), 418–425 (2011).
  • Kapitza C, Lynge J, During M et al. Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP1 analogue, in healthy male subjects. Presented at: 48th EASD Annual Meeting. Berlin, Germany, 1–5 October 2012.
  • Nauck MA, Petrie JR, Sesti G et al. The once-weekly human GLP1 analogue semaglutide provides significant reductions in HbA1c and bodyweight in patients with Type 2 diabetes. Presented at: 48th EASD Annual Meeting. Berlin, Germany, 1–5 October 2012.
  • Raz I, Fonseca V, Kipnes M et al. Efficacy and safety of taspoglutide monotherapy in drug-naive Type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled Phase 3 study (T-emerge 1). Diabetes Care 35(3), 485–487 (2012).
  • Fineman MS, Mace KF, Diamant M et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes. Obes. Metab. 14(6), 546–554 (2012).
  • Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in Type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes. Obes. Metab. 11(Suppl. 3), 26–34 (2009).
  • Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with Type 2 diabetes. Cardiovasc. Diabetol. 10, 22 (2011).
  • Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117(18), 2340–2350 (2008).
  • Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141(6), 413–420 (2004).
  • Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229–234 (1998).
  • Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54(1), 146–151 (2005).
  • Sivertsen J, Rosenmeier J, Holst JJ, Vilsbøll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9(4), 209–222 (2012).
  • Nyström T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287(6), E1209–E1215 (2004).
  • Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 125(1–3), 173–177 (2005).
  • Kavianipour M, Ehlers MR, Malmberg K et al. Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24(4), 569–578 (2003).
  • Noyan-Ashraf MH, Momen MA, Ban K et al. GLP1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4), 975–983 (2009).
  • Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109(8), 962–965 (2004).
  • Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110(8), 955–961 (2004).
  • Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L. Initial experience with GLP1 treatment on metabolic control and myocardial function in patients with Type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res. 1(1), 40–43 (2004).
  • Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Cardiac. Failure 12, 694–699 (2006).
  • Bao W, Aravindhan K, Alsaid H et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS ONE 6(8), e23570 (2011).
  • Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with Type 2 diabetes prescribed the glucagon-like peptide 1 (GLP1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34(1), 90–95 (2011).
  • Monami M, Cremasco F, Lamanna C et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp. Diabetes Res. 2011, 215764 (2011).
  • Okerson T, Chilton RJ. The cardiovascular effects of GLP1 receptor agonists. Cardiovasc. Ther. 30(3), e146–e155 (2012).
  • Robinson LE, Holt TA, Rees K et al. Effects of exenatide and liraglutide on heart rate, blood pressure, and bodyweight: systematic review and meta-analysis. Br. Med. J. 3(1) (2013).
  • Buse JB, Rosenstock J, Sesti G et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), 39–47 (2009).
  • Singh S, Chang HY, Richards MS, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in Type 2 diabetes mellitus. JAMA Intern. Med. 25, 1–6 (2013).
  • Bjerre Knudsen L, Madsen LW, Andersen S et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid c-cells causing calcitonin release and c-cell proliferation. Endocrinology 151(4), 1473–1486 (2010).
  • Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of Type 2 diabetes patients in the United States. J. Med. Econ. 15(4), 654–663 (2012).
  • Gaebler JA, Soto-Campos G, Alperin P et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of Type 2 diabetes: a simulation analysis. Vasc. Health Risk Manag. 8, 255–264 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.